Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Transcriptomic Signatures of T and CAR T Cells Aspredictors of Treatment Outcomes Inrelapsed/Refractory Large Diffuse B Cell Lymphoma

Ismael De La Iglesia San Sebastián, Sara Fernández de Córdoba-Oñate, Mariana Bastos-Oreiro, Raquel Fernández González, Javier Anguita, Ignacio Gómez-Centurión, Rebeca Bailen, Mi Kwon, Ramon Garcia-Sanz, Ismael Buño, Carolina Martinez-Laperche

Blood (2024) 144 (Supplement 1): 7150.

https://doi.org/10.1182/blood-2024-207145

Published: 2024

Journal Articles

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Catherine S. Diefenbach, Andrew D. Zelenetz, Charles Herbaux, Monica Tani, Roch Houot, Mariana Bastos-Oreiro, Hervé Tilly, Thomas Gastinne, Catherine Thieblemont, Wilfred Leung, Katerina Hatzi, Murali Kesavan, Simona Barlera, Michelle Boyer, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 577.

https://doi.org/10.1182/blood-2024-198624

Published: 2024

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024

Journal Articles

Improved Genetic Characterization of Aggressive B-Cell Lymphoma at Diagnosis Using Next-Generation Sequencing

Mariana Bastos-Oreiro, Ismael De La Iglesia, Maria Chicano, Marina Gomez Llobell, Francisco Diaz Crespo, Paula Fernández Caldas-González, Juan Carlos Triviño, Raquel Fernandez, Ramon Garcia-Sanz, Ismael Buño, Carolina Martinez-Laperche

Blood (2024) 144 (Supplement 1): 6229.

https://doi.org/10.1182/blood-2024-208216

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Blood (2024) 144 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2024-205005

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

Carolina Martinez-Laperche, Gonzalo Del Campo-Balguerias, Ismael De La Iglesia San Sebastián, Juan Carlos Triviño, Francisco Diaz Crespo, Rebeca Bailen, Raquel Fernandez-Gonzalez, Sara Fernandez-de Córdoba, Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Paula Fernández Caldas-González, Ignacio Gómez-Centurión, Mi Kwon, Javier Anguita, Ramon García-Sanz, Ismael Buño, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 2044.

https://doi.org/10.1182/blood-2024-209913

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Blood (2024) 144 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2024-199742

Published: 2024

Journal Articles

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Almudena Cabero Martínez, Ana García Bacelar, Begoña Mendibil Esquisabel, Javier Nuñez Cespedes, Ana Jiménez Ubieto, Eukene Gainza Gonzalez, Elena Perez Ceballos, Beatriz De La Cruz, Ana Garcia Noblejas, Paula Fernández-Caldas, Norma C. Gutierrez, Blanca Sánchez-González, Rocío Figueroa Mora, Alberto Lopez Garcia, Daniel García Belmonte, Maria Sanchez de Castro, Estefania Cerezo Velasco, Xabier Martin Martitegui, Hugo Daniel Luzardo Henríquez, Jordina Rovira, Luis Antonio Lopez Gomez, Jackeline Solano, Ana Torres Tienza, Maria Stefania Infante, Raquel Santiago Alonso, Raquel Del Campo, Dunia De Miguel Llorente, Alicia Roldán-Pérez, Emilia Pardal, Beatriz Gonzalez Mena, Miguel Ángel Rodríguez Gil, Nazaret Domínguez Velasco, Albert Blanco Juan, Maria Alejandra Blum Dominguez, Javier López Marin, María Peñarrubia-Ponce, Mariana Bastos-Oreiro, Alejandro Martín García-Sancho

Blood (2024) 144 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2024-198904

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Leyre Bento, Fernando Martín Moro, Antonio Gutierrez, Ana Jiménez Ubieto, Alberto López, Blanca Sánchez González, Belén Navarro, Alicia Segura, Mireia Franch, Ana García-Noblejas, Eva Donato, Alejandro Martín García-Sancho, Beatriz De La Cruz, Alfonso Ortiz Algarra, Roberto Trelles-Martínez, Javier López, Carlos Grande, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2024-203615

Published: 2024

Journal Articles

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Blood (2023) 142 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2023-186101

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

NARROW

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Transcriptomic Signatures of T and CAR T Cells Aspredictors of Treatment Outcomes Inrelapsed/Refractory Large Diffuse B Cell Lymphoma

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Improved Genetic Characterization of Aggressive B-Cell Lymphoma at Diagnosis Using Next-Generation Sequencing

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only